Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan 23;6(2):124-127.
doi: 10.1016/j.jdcr.2019.12.001. eCollection 2020 Feb.

Recurrent systemic anaplastic large cell lymphoma: Rapid onset and resolution of cutaneous metastases

Jun Long  1 , Ali Rajabi-Estarabadi  1 , Natalie M Williams  1 , Pooja Gurnani  1 , Andrea Maderal  1 , George Elgart  1 , Keyvan Nouri  1
Affiliations
Case Reports

Recurrent systemic anaplastic large cell lymphoma: Rapid onset and resolution of cutaneous metastases

Jun Long et al. JAAD Case Rep. .
No abstract available

Keywords: ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; DLI, donor lymphocyte infusion; S-ALCL, systemic anaplastic large-cell lymphoma; SCT, stem cell transplant; anaplastic large cell lymphoma; anaplastic lymphoma kinase; donor lymphocyte I.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Gross appearance of skin lesions: multiple light pink annular papules and nodules with central ulceration on his face and neck. Photo was taken on February 14, 2019.
Fig 2
Fig 2
Histologic analysis of biopsy samples confirms the diagnosis of skin metastasis of ALK- systemic anaplastic large-cell lymphoma. ALK, Anaplastic lymphoma kinase.
Fig 3
Fig 3
The timeline of the patient's medical history (2014-2019). ALK, Anaplastic lymphoma kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; DLI, donor lymphocyte infusion; ICE, ifosfamide, carboplatin, etoposide; S-ALCL, systemic anaplastic large-cell lymphoma; SCT, stem cell transplant.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Al-Hamadani M., Habermann T.M., Cerhan J.R., Macon W.R., Maurer M.J., Go R.S. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–795. - PubMed
    1. Savage K.J., Harris N.L., Vose J.M. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–5504. - PubMed
    1. Parrilla Castellar E.R., Jaffe E.S., Said J.W. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480. - PMC - PubMed
    1. Mencia-Gutierrez E., Gutierrez-Diaz E., Salamanca J., Martinez-Gonzalez M.A. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL) Int J Dermatol. 2006;45(6):766–769. - PubMed
    1. Hernandez C., Puangsuvan S.N., Peterson A., Robinson J.K. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma. Clin Exp Dermatol. 2009;34(8):e722–e725. - PubMed

Publication types

LinkOut - more resources